FI54124C - Foerfarande foer framstaellning av terapeutiskt anvaendbara 5-(4-metyl-1-piperazinyl)-karbonyloxi-7-oxo-5,6-dihydropyrrolo(3,4-b)pyrazinderivat - Google Patents

Foerfarande foer framstaellning av terapeutiskt anvaendbara 5-(4-metyl-1-piperazinyl)-karbonyloxi-7-oxo-5,6-dihydropyrrolo(3,4-b)pyrazinderivat

Info

Publication number
FI54124C
FI54124C FI27/73A FI2773A FI54124C FI 54124 C FI54124 C FI 54124C FI 27/73 A FI27/73 A FI 27/73A FI 2773 A FI2773 A FI 2773A FI 54124 C FI54124 C FI 54124C
Authority
FI
Finland
Prior art keywords
therapeutic
dihydropyrrolo
carbonyloxy
piperazinyl
oxo
Prior art date
Application number
FI27/73A
Other languages
English (en)
Finnish (fi)
Other versions
FI54124B (fi
Inventor
Claude Cotrel
Claude Jeanmart
Mayer Naoum Messer
Original Assignee
Rhone Poulenc Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR7200505A external-priority patent/FR2166314A1/fr
Priority claimed from FR7239731A external-priority patent/FR2205318A2/fr
Application filed by Rhone Poulenc Sa filed Critical Rhone Poulenc Sa
Publication of FI54124B publication Critical patent/FI54124B/fi
Application granted granted Critical
Publication of FI54124C publication Critical patent/FI54124C/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FI27/73A 1972-01-07 1973-01-05 Foerfarande foer framstaellning av terapeutiskt anvaendbara 5-(4-metyl-1-piperazinyl)-karbonyloxi-7-oxo-5,6-dihydropyrrolo(3,4-b)pyrazinderivat FI54124C (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR7200505A FR2166314A1 (en) 1972-01-07 1972-01-07 6-substd 5-(4-methyl 1-piperazinyl)carbonyloxy 7-oxo - 5,6-dihydro-pyrrolo (3,4-b)pyrazines - tranquillizers and anticonvuls
FR7239731A FR2205318A2 (en) 1972-11-09 1972-11-09 6-substd 5-(4-methyl 1-piperazinyl)carbonyloxy 7-oxo - 5,6-dihydro-pyrrolo (3,4-b)pyrazines - tranquillizers and anticonvuls

Publications (2)

Publication Number Publication Date
FI54124B FI54124B (fi) 1978-06-30
FI54124C true FI54124C (fi) 1978-10-10

Family

ID=26216824

Family Applications (1)

Application Number Title Priority Date Filing Date
FI27/73A FI54124C (fi) 1972-01-07 1973-01-05 Foerfarande foer framstaellning av terapeutiskt anvaendbara 5-(4-metyl-1-piperazinyl)-karbonyloxi-7-oxo-5,6-dihydropyrrolo(3,4-b)pyrazinderivat

Country Status (22)

Country Link
US (1) US3862149A (enExample)
JP (3) JPS523952B2 (enExample)
AR (1) AR195097A1 (enExample)
AT (1) AT323181B (enExample)
AU (1) AU466586B2 (enExample)
BE (1) BE793730A (enExample)
CA (1) CA991183A (enExample)
CY (1) CY915A (enExample)
DD (1) DD102698A5 (enExample)
DE (1) DE2300491C3 (enExample)
DK (1) DK139359B (enExample)
FI (1) FI54124C (enExample)
GB (1) GB1358680A (enExample)
HK (1) HK60077A (enExample)
HU (1) HU164821B (enExample)
IE (1) IE37056B1 (enExample)
IL (1) IL41232A (enExample)
LU (1) LU66800A1 (enExample)
NL (1) NL7217852A (enExample)
NO (1) NO136843C (enExample)
OA (1) OA04285A (enExample)
SE (1) SE398503B (enExample)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR208414A1 (es) * 1974-11-07 1976-12-27 Rhone Poulenc Ind Procedimiento para obtener nuevos derivados de la((acil-4piperazinil-1)carboniloxi-5 pirrolinona-2)
FR2322601A1 (fr) * 1975-09-04 1977-04-01 Rhone Poulenc Ind Nouveaux derives de l'isoindoline, leur preparation et les compositions qui les contiennent
US4590189A (en) * 1982-04-02 1986-05-20 Takeda Chemical Industries, Ltd. Condensed pyrrolinone derivatives, their production and use
JPS6169773A (ja) * 1984-09-14 1986-04-10 Takeda Chem Ind Ltd イソインドリノン誘導体
JPS6297400U (enExample) * 1985-12-09 1987-06-20
FR2607504B1 (fr) * 1986-12-02 1989-01-27 Rhone Poulenc Sante Nouveaux derives de l'isoindolinone, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2671800B1 (fr) * 1991-01-17 1993-03-12 Rhone Poulenc Rorer Sa Derive de la 5h-pyrrolo[3,4-b]pyrazine optiquement actif, sa preparation et les compositions pharmaceutiques qui le contiennent.
US5786357A (en) * 1991-12-02 1998-07-28 Sepracor Inc. Methods and compositions for treating sleep disorders, convulsive seizures and other disorders using optically pure (+) zopiclone
WO1993010788A1 (en) * 1991-12-02 1993-06-10 Sepracor, Inc. Methods and compositions for treating sleep disorders, convulsive seizures, and other disorders using optically pure (-) zopiclone
AU3245593A (en) * 1991-12-02 1993-06-28 Sepracor, Inc. Methods and compositions for treating sleep disorders, convulsive seizures, and other disorders using optically pure (+) zopiclone
DE69910795T2 (de) 1998-06-09 2004-06-17 Takeda Chemical Industries, Ltd. Pharmazeutische kombination mit einer trizyclischen verbindung und mindestens einer von zolpidem, zopiclone und brotizolam, zur behandlung oder verhinderung von schlafstörungen
US6339086B1 (en) 1999-05-14 2002-01-15 Swpracor, Inc. Methods of making and using N-desmethylzopiclone
ES2203319B1 (es) * 2002-04-03 2005-03-01 Universidad De Oviedo Nuevos carbonatos opticamente activos como intermedios en la sintesis de (+)-zopiclona.
AU2004305563C1 (en) 2003-12-11 2011-07-07 Sunovion Pharmaceuticals Inc. Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
MX2008000249A (es) * 2005-07-06 2008-03-18 Sepracor Inc Combinaciones de eszopiclona y o-desmetilvenlafaxina y metodos de tratamiento de menopausia y trastornos del estado de animo, ansiedad y cognitivos.
CN101553217A (zh) 2005-07-06 2009-10-07 塞普拉科公司 艾司佐匹克隆与反式4－(3,4－二氯苯基)－1,2,3,4－四氢－n－甲基－1－萘胺或反式4－(3,4－二氯苯基)－1,2,3,4－四氢－1－萘胺的组合以及治疗绝经期和心境障碍、焦虑症和认知障碍的方法
WO2007025177A2 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
US7476737B2 (en) * 2005-09-05 2009-01-13 Dr. Reddy's Laboratories Limited Eszopiclone process
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Ｐｄｅ阻害による神経新生の調節
EP1942879A1 (en) * 2005-10-31 2008-07-16 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
WO2007088073A1 (en) * 2006-02-03 2007-08-09 Synthon B.V. Zopiclone resolution using l-tartaric acid
US20100216734A1 (en) * 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US20070244143A1 (en) * 2006-03-08 2007-10-18 Braincells, Inc Modulation of neurogenesis by nootropic agents
US20080027223A1 (en) * 2006-03-23 2008-01-31 Teva Pharmaceutical Industries Ltd. Polymorphs of eszopiclone malate
EP2007768A2 (en) * 2006-04-20 2008-12-31 Teva Pharmaceutical Industries Ltd Methods for preparing eszopiclone crystalline form a, substantially pure eszopiclone and optically enriched eszopiclone
CN101058581B (zh) * 2006-04-21 2011-06-08 天津天士力集团有限公司 右佐匹克隆中间体6-(5-氯-2-吡啶基)-5,7-二氧代-6,7-二氢-5H-吡咯并[3,4-b]吡嗪的制备方法
CA2651862A1 (en) * 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
EP2382975A3 (en) 2006-05-09 2012-02-29 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100009983A1 (en) * 2006-05-09 2010-01-14 Braincells, Inc. 5 ht receptor mediated neurogenesis
EP1904499A1 (en) * 2006-06-26 2008-04-02 Teva Pharmaceutical Industries Ltd Process for the preparation of zopiclone
US7998971B2 (en) * 2006-09-08 2011-08-16 Braincells Inc. Combinations containing a 4-acylaminopyridine derivative
AU2007299920A1 (en) * 2006-09-19 2008-03-27 Braincells, Inc. PPAR Mediated Modulation of Neurogenesis
US7786304B2 (en) * 2006-11-06 2010-08-31 Centaur Pharmaceutical Pvt. Ltd. Process for the preparation of eszopiclone
EP2032557A2 (en) * 2007-01-31 2009-03-11 Teva Pharmaceutical Industries Ltd. Methods for preparing eszopiclone
US20080305171A1 (en) * 2007-06-07 2008-12-11 Kristin Anne Arnold Pyrrolopyrazine, formulations, methods of manufacture, and methods of use there
WO2009002552A1 (en) * 2007-06-25 2008-12-31 Teva Pharmaceutical Industries Ltd. Racemization process of r-zopiclone
EP2020403A1 (en) 2007-08-02 2009-02-04 Esteve Quimica, S.A. Process for the resolution of zopiclone and intermediate compounds
WO2009063486A2 (en) * 2007-08-06 2009-05-22 Usv Limited Process for preparation of dextrorotatory isomer of 6-(5-chloro-pyrid-2-yi)-5-[(4-methyl -1-piperazinyl) carbonyloxy]-7-oxo-6,7-dihydro-5h-pyrrolo [3,4-b] pyrazine (eszopiclone)
WO2009087667A2 (en) * 2007-12-11 2009-07-16 Cipla Ltd. A new method for preparation of zopiclone and its polymorphs
US8268832B2 (en) * 2007-12-19 2012-09-18 Sunovion Pharmaceuticals Inc. Maleate salts of 6-(5-chloro-2-Pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
US8212036B2 (en) 2007-12-19 2012-07-03 Sunovion Pharmaceuticals Inc. Maleate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
US8198277B2 (en) 2007-12-19 2012-06-12 Sunovion Pharmaceuticals Inc. L-malate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
CA2812705C (en) * 2007-12-19 2015-08-18 Sunovion Pharmaceuticals Inc. Maleate, besylate and l-malate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5h-pyrrolo[3,4-b]pyrazine
US8269005B2 (en) * 2007-12-19 2012-09-18 Sunovion Pharmaceuticals Inc. L-malate salts of 6-(5-chloro-2-Pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-Oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
WO2009085988A1 (en) * 2007-12-19 2009-07-09 Sepracor Inc. Salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7- dihydro-5h-pyrrolo[3,4-b]pyrazine
US8198278B2 (en) 2007-12-19 2012-06-12 Sunovion Pharmaceuticals Inc. Besylate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
CN100467471C (zh) * 2007-12-19 2009-03-11 齐鲁天和惠世制药有限公司 佐匹克隆的制备方法
EP2391354B1 (en) 2009-01-30 2019-11-27 Sunovion Pharmaceuticals Inc. Coated tablets of 6-(5-chloro-2-pyridyl) -5-[ (4-methyl-1-piperazinyl) carbonyloxy]-7-oxo-6, 7-dihydro-5h-pyrrol o [3,4-b] pyrazine and process for preparation thereof
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
CN105399745A (zh) * 2015-12-17 2016-03-16 天津华津制药有限公司 一种吡嗪并羟基吡咯烷酮类化合物的制备方法
EP3468545A4 (en) 2016-06-08 2020-07-22 President and Fellows of Harvard College METHODS AND COMPOSITIONS FOR REDUCING TACTILE DYSFUNCTION AND ANXIETY ASSOCIATED WITH AUTISM SPECTRUM DISORDER, RETT SYNDROME AND FRAGILE X SYNDROME
CN106220630B (zh) * 2016-07-23 2019-12-10 迪嘉药业集团有限公司 一种n-取代吡咯并[3,4-b]吡嗪-5,7(6h)-二酮的制备方法
WO2019226808A1 (en) 2018-05-22 2019-11-28 President And Fellows Of Harvard College Compositions and methods for reducing tactile dysfunction, anxiety, and social impairment
US11434244B2 (en) 2018-05-29 2022-09-06 President And Fellows Of Harvard College Compositions and methods for reducing tactile dysfunction, anxiety, and social impairment
US12077512B2 (en) 2019-03-25 2024-09-03 President And Fellows Of Harvard College Compositions and methods for reducing tactile dysfunction, anxiety, and social impairment
CN114437027A (zh) * 2021-12-22 2022-05-06 深圳市祥根生物医药有限公司 一种佐匹克隆n-氧化杂质的制备方法

Also Published As

Publication number Publication date
IE37056B1 (en) 1977-04-27
SE398503B (sv) 1977-12-27
NO136843B (no) 1977-08-08
JPS535315B2 (enExample) 1978-02-25
HU164821B (enExample) 1974-04-11
BE793730A (fr) 1973-07-05
DE2300491C3 (de) 1978-05-18
GB1358680A (en) 1974-07-03
AU466586B2 (en) 1975-10-30
JPS5248688A (en) 1977-04-18
DK139359B (da) 1979-02-05
DD102698A5 (enExample) 1973-12-20
FI54124B (fi) 1978-06-30
IE37056L (en) 1973-07-07
NO136843C (no) 1977-11-16
IL41232A (en) 1975-12-31
US3862149A (en) 1975-01-21
AU5075473A (en) 1974-07-04
OA04285A (fr) 1979-12-31
JPS5231358B2 (enExample) 1977-08-13
JPS523952B2 (enExample) 1977-01-31
DK139359C (enExample) 1979-07-09
IL41232A0 (en) 1973-03-30
AT323181B (de) 1975-06-25
HK60077A (en) 1977-12-09
CY915A (en) 1977-12-23
DE2300491B2 (de) 1977-09-08
JPS4876892A (enExample) 1973-10-16
JPS5248687A (en) 1977-04-18
CA991183A (fr) 1976-06-15
LU66800A1 (enExample) 1973-07-18
AR195097A1 (es) 1973-09-10
NL7217852A (enExample) 1973-07-10
DE2300491A1 (de) 1973-07-19

Similar Documents

Publication Publication Date Title
FI54124B (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbara 5-(4-metyl-1-piperazinyl)-karbonyloxi-7-oxo-5,6-dihydropyrrolo(3,4-b)pyrazinderivat
SE402592B (sv) Forfarande for framstellning av 2-alkyl-3-acyl-pyrazolo(1,5-a)pyridiner
NO144885C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive benzodiazepinderivater
SE432767B (sv) Forfarande for framstellning av oxazolo-(5,4-b)-pyridiner
NO138566C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 2,1,3-benzotiadiazol-derivater
NO145056C (no) (s)-1-aryloksy-2-propanolderivater for fremstilling av terapeutisk aktive (s)-1-aryloksy-3-amino-2-propanolderivater
NO146396C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive pyrimidinderivater.
SE419990B (sv) Analogiforfarande for framstellning av s-triazolo(4,3-b)pyridaziner
SE381047B (sv) Forfarande for framstellning av 3-substituerade 1,2-bensisoxazolderivat
SE399879B (sv) Kemiska mellanprodukter till anvendning for framstellning av terapeutiskt verdefulla 1,2,3,4-tetrahydro-4-fenyl-isokinolinderivat
FI54312C (fi) Foerfarande foer framstaellning av tieno-(2,3-d)pyrimidinderivat med avsoendring av urinsyra i urin utoekande
NO137966C (no) Analogifremgangsmaate til fremstilling av antibakterielt virksomme 5-oksopyrido-(2,3-d)-pyrimidinderivater
SE402012B (sv) Analogiforfarande for framstellning av s-triazolo(1,5-a)(1,4)diazepinderivat
SE412234B (sv) Analogiforfarande for framstellning av s-triazolo(1,5-a)pyridinderivat
SE410604B (sv) Analogiforfarande for framstellning av pyrazolo(3,4-e)(1,4)diazepinforeningar
FI55660C (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbara pyrazolo(3,4-b)pyridinderivat
CA988931A (en) Sulfur derivatives of pyrazolo(3,4-b)pyridines
SE397827B (sv) Forfarande for framstellning av 1-aminometyl-2,2-difenylcyklopropankarboxamidderivat med terapeutisk verkan
FI54712C (fi) Foerfarande foer framstaellning av terapeutiskt aktiva 5-((4-metylpiperazin-1-yl)karbonyloxi)-7-oxo-2,3,6,7-tetrahydroditiino (1,4)2,3-c)pyrroler
SE380804B (sv) Anologiforfarande for framstellning av s-triazolo (1,5-a) (1,4)
FI56386B (fi) Foerfarande foer framstaellning av oktahydro-oxazolo 3,2-a pyrrolo 2,1-c pyrazin-derivat
SE397832B (sv) Analogiforfarande for framstellning av s-triazolo(4,3-a)(1,4)bensodiazepinderivat
SE382983B (sv) Analogiforfarande for framstellning av oxazolo(3,2-d) (1,4) bensodiazepinderivat
SE408302B (sv) Forfarande for framstellning av 1,4-bensodiazepin-derivat
SE381046B (sv) Forfarande for framstellning av 1,4-bensodiazepinderivat